In this newsletter, we are pleased to share brief, but in-depth interviews with IO leadership and the work they are advancing in immuno-resistance and rational combinations, strategies to expand the CAR-T cell therapeutic window, next-generation engineered T-cell therapies, recent developments in the field of T-cell exhaustion, ongoing CAR-T cell therapy clinical trials for brain cancers, managing through the pandemic and new research to better understand and develop cell therapies…
